Neurofibromatosis Type 1 Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - Novartis, Fosun Pharma, SpringWorks, NFlection, Inc., AstraZeneca

DelveInsight's "Neurofibromatosis Type 1 Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neurofibromatosis Type 1, historical and forecasted epidemiology as well as the Neurofibromatosis Type 1 market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Neurofibromatosis Type 1 market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Type 1 Market Forecast
https://www.delveinsight.com/report-store/neurofibromatosis-type-1-nf1-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Neurofibromatosis Type 1 Market Report:
• The Neurofibromatosis Type 1 market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As per the study by Le and Bedocs (2022), Neurofibromatosis type 1 makes up about 96% of all neurofibromatosis cases. While Neurofibromatosis type 2 makes up about 3% of all cases. It occurs equally between gender and races. Fifty percent of patients have a spontaneous mutation, and the other half have an inherited mutation
• With the advancement in research, many pharmaceutical companies are stepping into this disease area. Some emerging drugs include FCN-159, Mirdametinib, NFX-179 Gel, and others
• In the study conducted by Iheanacho et al. (2021), to identify the epidemiological and clinical burden associated with plexiform neurofibromas in pediatric NF1, evidence confirmed that NF-1 is rare but that occurrence may differ geographically
• In a study by Ejerskov et al. (2021), out of total 17 patients with a mosaic form of neurofibromatosis type1 (NF1), five patients (30%) had a plexiform neurofibroma
• Key Neurofibromatosis Type 1 Companies: Novartis, Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., AstraZeneca, SpringWorks Therapeutics, Inc.Shanghai Kechow Pharma, Shanghai Fosun Pharma, Chia Tai Tianqing Pharma, Recursion Pharma, Betta Pharma, Shandong Simcere-Medgenn Bio-pharmaceutical, NFlection Therapeutics, and others
• Key Neurofibromatosis Type 1 Therapies: FCN-159, Mirdametinib, NFX-179, Selumetinib, Mirdametinib, HL-085, AL2846, RAD001, Everolimus, REC-2282, Icotinib, Endostatin, NFX-179, and others
• The Neurofibromatosis Type 1 market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurofibromatosis Type 1 pipeline products will significantly revolutionize the Neurofibromatosis Type 1 market dynamics.

Neurofibromatosis Type 1 Overview
Neurofibromatosis are a group of genetic disorders that cause tumors to form on nerve tissue. There are three types of neurofibromatosis: neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2) and schwannomatosis.

Get a Free sample for the Neurofibromatosis Type 1 Market Report
https://www.delveinsight.com/sample-request/neurofibromatosis-type-1-nf1-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurofibromatosis Type 1 Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neurofibromatosis Type 1 Epidemiology Segmentation:
The Neurofibromatosis Type 1 market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Neurofibromatosis Type 1
• Prevalent Cases of Neurofibromatosis Type 1 by severity
• Gender-specific Prevalence of Neurofibromatosis Type 1
• Diagnosed Cases of Episodic and Chronic Neurofibromatosis Type 1

Download the report to understand which factors are driving Neurofibromatosis Type 1 epidemiology trends @ Neurofibromatosis Type 1 Epidemiology Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-type-1-nf1-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurofibromatosis Type 1 Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis Type 1 market or expected to get launched during the study period. The analysis covers Neurofibromatosis Type 1 market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurofibromatosis Type 1 Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurofibromatosis Type 1 Therapies and Key Companies
• FCN-159: Fosun Pharmaceutical
• Mirdametinib: SpringWorks Therapeutics
• NFX-179 Gel: NFlection Therapeutics, Inc.
• Selumetinib: AstraZeneca
• Mirdametinib: SpringWorks Therapeutics, Inc.
• HL-085: Shanghai Kechow Pharma
• FCN-159: Shanghai Fosun Pharma
• AL2846: Chia Tai Tianqing Pharma
• RAD001: Everolimus: Novartis
• REC-2282: Recursion Pharma
• Icotinib: Betta Pharma
• Endostatin: Shandong Simcere-Medgenn Bio-pharmaceutical
• NFX-179: NFlection Therapeutics

Discover more about therapies set to grab major Neurofibromatosis Type 1 market share @ Neurofibromatosis Type 1 Treatment Market
https://www.delveinsight.com/sample-request/neurofibromatosis-type-1-nf1-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Neurofibromatosis Type 1 Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neurofibromatosis Type 1 Companies: Novartis, Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., AstraZeneca, SpringWorks Therapeutics, Inc.Shanghai Kechow Pharma, Shanghai Fosun Pharma, Chia Tai Tianqing Pharma, Recursion Pharma, Betta Pharma, Shandong Simcere-Medgenn Bio-pharmaceutical, NFlection Therapeutics, and others
• Key Neurofibromatosis Type 1 Therapies: FCN-159, Mirdametinib, NFX-179, Selumetinib, Mirdametinib, HL-085, AL2846, RAD001, Everolimus, REC-2282, Icotinib, Endostatin, NFX-179, and others
• Neurofibromatosis Type 1 Therapeutic Assessment: Neurofibromatosis Type 1 current marketed and Neurofibromatosis Type 1 emerging therapies
• Neurofibromatosis Type 1 Market Dynamics: Neurofibromatosis Type 1 market drivers and Neurofibromatosis Type 1 market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neurofibromatosis Type 1 Unmet Needs, KOL's views, Analyst's views, Neurofibromatosis Type 1 Market Access and Reimbursement

To know more about Neurofibromatosis Type 1 companies working in the treatment market, visit @ Neurofibromatosis Type 1 Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/neurofibromatosis-type-1-nf1-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Neurofibromatosis Type 1 Market Report Introduction
2. Executive Summary for Neurofibromatosis Type 1
3. SWOT analysis of Neurofibromatosis Type 1
4. Neurofibromatosis Type 1 Patient Share (%) Overview at a Glance
5. Neurofibromatosis Type 1 Market Overview at a Glance
6. Neurofibromatosis Type 1 Disease Background and Overview
7. Neurofibromatosis Type 1 Epidemiology and Patient Population
8. Country-Specific Patient Population of Neurofibromatosis Type 1
9. Neurofibromatosis Type 1 Current Treatment and Medical Practices
10. Neurofibromatosis Type 1 Unmet Needs
11. Neurofibromatosis Type 1 Emerging Therapies
12. Neurofibromatosis Type 1 Market Outlook
13. Country-Wise Neurofibromatosis Type 1 Market Analysis (2019-2032)
14. Neurofibromatosis Type 1 Market Access and Reimbursement of Therapies
15. Neurofibromatosis Type 1 Market Drivers
16. Neurofibromatosis Type 1 Market Barriers
17. Neurofibromatosis Type 1 Appendix
18. Neurofibromatosis Type 1 Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Neurofibromatosis Type 1 Pipeline https://www.delveinsight.com/report-store/neurofibromatosis-type-1-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Neurofibromatosis Type 1 Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Neurofibromatosis Type 1 market. A detailed picture of the Neurofibromatosis Type 1 pipeline landscape is provided, which includes the disease overview and Neurofibromatosis Type 1 treatment guidelines.
Neurofibromatosis Type 1 Epidemiology https://www.delveinsight.com/report-store/neurofibromatosis-type-1-nf1-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neurofibromatosis Type 1 Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neurofibromatosis Type 1 epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.